39 results about "Retinal Disorder" patented technology

The invention provides a retina image registration method and system based on grid supervision and key point learning, and belongs to the technical field of medical image processing. The method comprises the following steps: acquiring an RGB fundus image pair; encoding the RGB eye fundus image pair through a shared feature extraction branch to obtain a down-sampling feature map; processing the down-sampling feature graph through a key point extraction branch and a descriptor decoder branch respectively, and extracting a key point probability graph and a feature descriptor; predicting the offset of the key points in the local window based on the paired feature descriptors through a key point offset prediction module; and carrying out position calibration on the key points in the key point probability graph based on the offset, and outputting a registered image. According to the method, self-supervised training is realized by using dense gridding marking points, and manual marking is not needed; through lightweight network design and a key point offset calibration mechanism, high registration precision is maintained while the parameter quantity is significantly reduced, and the method is suitable for clinical real-time deployment and retinal disease analysis.

The present invention provides a multiomics approach, which integrate single-cell RNA-sequencing (scRNA-seq) and spatiotemporal transcriptomics (ST) offering potential for dissecting transcriptional networks and revealing cell-cell interactions involved in biomolecular pathomechanisms. The present invention also provides a multimodal approach combining high-throughput scRNA-seq and ST to elucidate XLRS-specific transcriptomic signatures in two XLRS-like models with retinal splitting phenotypes, including genetically engineered (Rs1emR209C) mice and patient-derived retinal organoids harboring the same patient-specific p.R209C mutation. Through multiomics transcriptomic analysis, the endoplasmic reticulum (ER) stress / eIF2 signaling, mTOR pathway, and the regulation of eIF4 and p70S6K pathways as chronically enriched and highly conserved disease pathways between two XLRS-like models are identified. Western blots and proteomics analysis validated the occurrence of unfolded protein responses, chronic eIF2α signaling activation, and chronic ER stress-induced apoptosis. Furthermore, therapeutic targeting of the chronic ER stress / eIF2α pathway activation synergistically enhanced the efficacy of AAV mediated RS1 gene delivery, ultimately improving bipolar cell integrity, postsynaptic transmission, disorganized retinal architecture and electrophysiological responses. Collectively, the complex transcriptomic signatures obtained from Rs1emR209C mice and patient-derived retinal organoids using the multiomics approach provide opportunities to unravel potential therapeutic targets for incurable retinal diseases, such as XLRS.

The application provides an OCTA fundus image generation system, method, medium and device based on Mamba and diffusion model, the application effectively predicts the diffusion noise of the accurate OCTA image from the potential noise of the OCT by designing a unique Mamba block, reduces the artifacts of the generated image, and improves the contrast of the OCTA image generation. Secondly, the proposed bidirectional Bow scanning scheme effectively alleviates the mechanism challenge of the original Mamba scanning, enhances the spatial continuity of the generated OCTA image, and improves the blood vessel extension of the generated image. In addition, the designed conditional prompt improves the understanding of the OCT image in combination with the Mamba block and the diffusion model, and further improves the authenticity of the generated fundus OCTA image. The experimental verification on two public data sets of OCTA500-3M and OCTA500-6M and a private data set respectively reaches 87.5% and 88.1% of SSIM, indicating that the application can fully utilize the fundus OCT image information and effectively generate high-quality fundus OCTA images, providing a new possibility for low-cost screening of retinal diseases.

The application provides a FFA image generation system, method, medium and device based on a dual-domain constraint Mamba diffusion model, which integrates dual spatial and frequency domain constraints for cross-modal generation of FFA images from CFP images. Through a learnable wavelet feature extractor, the key frequency components of blood vessels are effectively extracted from the fundus CFP image, enhancing the structured guidance of the vascular edge representation in the generated FFA image. In the spatial domain, through a dual-pyramid feature extractor, the local details and global semantics of the fundus lesion area are effectively fused, improving the consistency of the lesion representation in the generated FFA image. The dual-domain conditional Mamba module serves as the denoising core, effectively coordinating spatial and frequency information to improve the clarity and accuracy of the image. The application is verified on the Hajeb, MPOS and clinical data sets, with PSNR reaching 30.11 and 29.40, effectively generating high-quality FFA images that retain vascular details, providing a new method for retinal disease screening.

Systems and relative method of monitoring the state of a subject's retinal disease employ remote based OCT imaging of a subject's retina. A method includes receiving optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina. The OCT image data of the retina is processed to determine a series of measured extent values. Each of the one or more measured extent values is indicative of a respective extent of the retinal disease.

The invention discloses an OCTA image multi-target segmentation method based on an attention enhancement full-resolution network. According to the method, OCTA three-dimensional volume data is used as input, a height dimension is mapped to a channel dimension through Squeeze operation, and lossless dimension reduction is carried out; an attention-enhanced full-resolution module ARCB is constructed in combination with an improved Recurrent ConvNeXt module and an improved attention mechanism ES-CPCA, channel relation modeling and global context sensing are enhanced under the condition that downsampling is not carried out, and features of four types of structures including blood capillaries, arteries, veins and central non-vascular regions are considered. According to the method, the average segmentation precision and robustness of multi-target segmentation can be improved under the condition that only OCTA volume data is used, and a reliable basis can be provided for quantitative evaluation of retinal diseases.

The present disclosure provides for one or more embodiments for treating retinal degenerative disorders in a subject by administering to the subject an effective amount of allogeneic mesenchymal stem cells to the subject's suprachoroidal area. Allogeneic mesenchymal stem cells, when used in the disclosed treatment regimen, may exhibit anti-inflammatory, immunomodulatory, anti-fibrotic, pro-vascular, and / or pro-regenerative processes. Thus, allogeneic mesenchymal stem cells may be understood to have the potential to target and treat multiple pathological targets implicated in retinal degenerative disorders, including retinal disorders characterized by drusen accumulation, some of which have inherited forms.

The present application relates to a preparation method and application of photoreceptor precursor cells of human embryonic stem cell-derived retinal organoids, and belongs to the field of biotechnology and stem cell engineering. The present application constructs a lentiviral vector carrying an exogenous target gene and infects human embryonic stem cells to obtain a stable expression of engineered stem cell clone group by screening; the clone group is subjected to three-dimensional differentiation, and sequentially undergoes the formation of a blastoid, neural epithelial induction and retinal layering stage to obtain a retinal organoid; finally, the co-expression of photoreceptor precursor cell markers and exogenous genes in the organoid is identified. The present application realizes stable integration of genes at the source of stem cells, avoids the problem of low infection efficiency in the later stage, and provides a complete standardized scheme from gene modification, directional differentiation to function verification. The engineered photoreceptor precursor cells obtained by the method have important application value in the construction of retinal disease models, drug screening and cell therapy development.

The present invention relates to sitagliptin or a pharmaceutically or veterinary acceptable salt thereof for use in the local eye treatment of neovascular retinal diseases. The invention also encompasses pharmaceutical or veterinary compositions for use in the local treatment of these diseases.

Provided herein are methods of treating a subject with a complement pathway inhibitor based on the subject's complement pathway activity. Also provided herein are methods of stratifying a subject into three groups based on the subject's complement pathway activity: hyperactive, homeostatic, and hypoactive, and administering an effective treatment (e.g., complement pathway inhibitors).

Provided are a photoreceptor cell-specific bidirectional promoter and the use thereof. Specifically, the present invention relates to a new photoreceptor cell-specific bidirectional promoter, an expression cassette, vector, virus particle, cell and pharmaceutical composition containing the bidirectional promoter, and the use thereof in the treatment of ocular diseases such as retinal diseases.

The present invention relates to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, in rescuing or restoring retinal function, rescuing or restoring retinal structure, and / or rescuing or restoring choroidal structure and / or function in chronic retinal disorders and other disorders.

rAAV particles comprising a new capsid variant, AAV44.9(E531D) are described herein, as well as a polynucleotide encoding same, and the use of the rAAV particles in the treatment of the eye, including treatment of retinal disorders. The disclosure also shows that the rAAV particles comprising an AAV44.9(E531D) capsid exhibit enhanced lateral spread after subretinal injection to a fovea of the subject, wherein detachment of the fovea is minimized. Methods of treatment comprising administering rAAV particles to a mammal in need thereof, and methods of transducing photoreceptor and RPE cells with rAAV particles, are also provided.

Systems and methods are provided for the automated quantitative assessment of the retinal microvascular system and the quantification of microvascular properties for the diagnosis and treatment of retinal and extraretinal diseases.

A clinical decision support system for retinal diseases processes OCT retinal scan images to enhance certain aspects of speckle, which has been found to include relevant information that can be used to enhance the diagnosis and classification of the severity and progression of any disease found in the retina scan image. A copy of the original OCT retinal scan image is processed using a shifted window transformer block to enhance the relevant speckle information, and combine it with the original image, which is then evaluated by a trained system to classify the retinal features, including the speckle.

A patient's retinal health can be evaluated via a virtual reality (VR) system, which can include a VR headset in electronic communication with a computing device. The VR headset can scan the patient's retinas using sensors and cameras. The computing device can cause a first vision test to be displayed on the screens of the VR headset. Using varying combinations of sensors, cameras, probes, and microphones, the VR headset collects data about the patient as she responds to the first vision test. Optionally, the computing device can cause a second vision test to be displayed on the screens, where the second vision test can be constructed on the patient's responses to the first vision test.

The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more of Norrie disease, age related hearing loss, diabetic maculopathy and retinopathy, retinal neovascularisation, retinal exudation, retinopathy of prematurity (ROP), Familial exudative vitreoretinopathy (FEVR), Coats disease, and other NDP-related diseases, or other beta catenin signalling-related retinal diseases.

Provided herein are methods of enriching for photoreceptors and photoreceptor precursor cells from mixed cell populations. Such enriched populations of photoreceptors and photoreceptor precursor cells can be used as cell therapies for the treatment of retinal disorders.

Provided herein are methods of using Compound 1, or a pharmaceutically acceptable form thereof, for treating retinal disease, including in combination with a VEGF / VEGFR signaling pathway inhibitor.

The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for preventing the progression of diabetic retinopathy, diabetic macular edema, and / or other retinal disorders and / or other disorders.

The present invention relates to photoreceptor cell-specific bidirectional promoters and uses thereof. In particular, the present invention relates to a novel photoreceptor cell-specific bidirectional promoter, expression cassettes, vectors, viral particles, cells and pharmaceutical compositions comprising the bidirectional promoter, and uses thereof for treating eye diseases, such as retinal diseases.

This disclosure features clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or disease (e.g., an ocular surface disease, corneal disease or retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.

A method for making a prediction regarding a malady in a retina of a subject, the method including: (a) receiving at least one retinal image of the retina; (b) calculating a prediction about the retina based on the at least one retinal image of the retina using at least one specialized machine learning (ML) model, the prediction pertaining to whether the malady will develop or manifest or progress in the retina within a time-period.

The invention provides a multi-modal retinal disease intelligent auxiliary diagnosis system, which comprises an image preprocessing module used for processing a binocular fundus image uploaded by a user; the disease classification module is used for extracting global features and local lesion details by adopting a dual-channel DINOv2 model, initializing weights in a data set through transfer learning, performing fine adjustment on the fundus image data set, and performing fundus multi-label classification; and the batch processing module is used for disassembling batch binocular eye fundus image processing tasks into independent sub-tasks based on a distributed task scheduling and dynamic resource allocation technology, and distributing the independent sub-tasks to a plurality of edge computing nodes for parallel processing. According to the method, a multi-label independent classifier is designed, eight independent three-layer MLP classifiers are adopted, and each classifier focuses on single pathological feature modeling. Through parameter space decoupling design, gradient conflicts among multiple labels are avoided, and accurate capture of heterogeneity pathologies such as diabetes microvascular leakage characteristics and glaucoma optic cup morphological parameters is ensured.

The present disclosure provides nanoparticle compositions for targeted drug delivery to retinal cells. The nanoparticles comprise a porous core that is at least partially coated with an ionic liquid. Targeting moieties conjugated to the core direct the nanoparticles to retinal cells. In one embodiment, the nanoparticle comprises polymeric bridged periodic mesoporous organosilica (PMO) - amino acid ionic liquid, linked to antibodies specific to retinal ganglion cells (RGCs). Also provided are methods of preparing the nanoparticles and methods of using the nanoparticles for treatment of retinal diseases.

The present invention relates to nucleic acid molecules encoding angiostatin, transgene expression cassettes comprising the nucleic acid molecules, and gene delivery systems comprising the transgene expression cassettes. The transgene expression cassettes of the present invention are useful in the treatment of various retinal diseases in which neovascularization is a major pathological mechanism, as well as various cancers.

This invention proposes a retinal image registration method and system based on grid supervision and keypoint learning, belonging to the field of medical image processing technology. The method includes: acquiring RGB fundus image pairs; encoding the RGB fundus image pairs through a shared feature extraction branch to obtain downsampled feature maps; processing the downsampled feature maps through a keypoint extraction branch and a descriptor decoder branch respectively to extract keypoint probability maps and feature descriptors; predicting the offset of keypoints within a local window based on paired feature descriptors using a keypoint offset prediction module; calibrating the positions of keypoints in the keypoint probability map based on the offsets; and outputting the registered image. This invention utilizes densely gridded annotation points for self-supervised training, eliminating the need for manual annotation; through lightweight network design and a keypoint offset calibration mechanism, it maintains high registration accuracy while significantly reducing the number of parameters, making it suitable for real-time clinical deployment and retinal disease analysis.

The present invention relates to the treatment of inherited retinal diseases using stem cell therapy. In particular, the present disclosure relates to methods of using photoreceptor precursor cells to treat primary photoreceptor diseases via surgical administration to the eye of a subject.

A method includes receiving an electronic fundus scan. The method also includes determining retinal disease information based on receiving the electronic fundus scan.

The present application relates to compositions and methods for rescuing retinal and choroidal structures and functions. The present invention relates to the use of anti-hemi-channel compounds, including anti-connexin 43 hemi-channel open compounds, to rescue or restore retinal function, to rescue or restore retinal structure, and / or to rescue or restore choroidal structure and / or function in chronic retinal disorders and other disorders.